Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Italian Real-World Experience of Gilteritinib Monotherapy in Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Preliminary Results

Blood (2024) 144 (Supplement 1): 5188.

https://doi.org/10.1182/blood-2024-205427

Published: 2024

Journal Articles

Rare Types of NPM1 Mutations Share a Similar Molecular Background to the Common NPM1 Variant and Have No Impact on Survival in Adults with Acute Myeloid Leukemia

Valentina Fabiola Ilenia Sangiorgio, Rocco Piazza, Monica Fumagalli, Carlo Gambacorti-Passerini, Mariarita Sciumè, Daniele Ramazzotti

Blood (2024) 144 (Supplement 1): 2936.

https://doi.org/10.1182/blood-2024-202884

Published: 2024

Journal Articles

Outpatient Administration of First Cycle Azacitidine-Venetoclax in Acute Myeloid Leukemia Patients Compared to Inpatient Care: Preliminary Results of a Single-Center Retro-Prospective Study

Arianna Zappaterra, Caterina Brambilla, Beatrice Manghisi, Stefano Bonfanti, Maria Kogan, Paola Perfetti, Lorenza Maria Borin, Andrea Carrer, Luisa Verga, Carlo Gambacorti-Passerini, Monica Fumagalli

Blood (2024) 144 (Supplement 1): 6053.

https://doi.org/10.1182/blood-2024-202309

Published: 2024

Journal Articles

Final Analysis of the Italian Campus ALL Observational Study on 476 Older Patients with Philadelphia-Negative Acute Lymphoblastic Leukemia

Marco Cerrano, Lazzarotto Davide, Eleonora Boscaro, Erika Borlenghi, Ilaria Tanasi, Patrizia Chiusolo, Paola Minetto, Francesco Grimaldi, Michelina Dargenio, Matteo Leoncin, Silvia Trappolini, Cristina Papayannidis, Fabio Forghieri, Carmela Gurrieri, Patrizia Zappasodi, Roberta La Starza, Nicola Fracchiolla, Federica Di Biase, Maria Ilaria Del Principe, Marzia Defina, Crescenza Pasciolla, Benedetta Cambò, Federico Mosna, Daniela Pietrasanta, Sabrina Mariani, Valentina Mancini, Fabio Guolo, Federico Lussana, Elisabetta Todisco, Mario Annunziata, Valeria Calafiore, Maria Ciccone, Matteo Piccini, Matteo Emidio Dragani, Beatrice Sani, Endri Mauro, Claudia Basilico, Beatrice De Marco, Marco Antonacci, Laura Forlani, Monica Fumagalli, Fabio Trastulli, Monia Lunghi, Prassede Salutari, Sara Mastaglio, Sabina Chiaretti, Anna Candoni, Felicetto Ferrara, Giovanni Pizzolo, Robin Foà, Massimiliano Bonifacio

Blood (2024) 144 (Supplement 1): 113.

https://doi.org/10.1182/blood-2024-206854

Published: 2024

Journal Articles

Venetoclax and Hypomethylating Agents Confirmed to be Standard Therapy in De Novo and ELN17 Not Adverse Acute Myeloid Leukemia Patients, Unfit for Chemotherapy According to SIE/Sies/GITMO Criteria. a Multicentric Real-Life Study on 379 Patients, By the Hematological Network Rete Ematologica Lombarda (REL)

Blood (2024) 144 (Supplement 1): 2863.

https://doi.org/10.1182/blood-2024-202530

Published: 2024

Journal Articles

CPX-351 Induces High Rate of Complete Remission in the New ICC/ELN 2022 Adverse-Risk Entity ‘AML with MDS-Related Gene Mutations’: Evidence from a Large Real-World Italian Study

Blood (2024) 144 (Supplement 1): 2849.

https://doi.org/10.1182/blood-2024-210042

Published: 2024

Journal Articles

Multiparametric Flow Cytometry-MRD Assay: Lesson from Phase II Trail REL AML 001

Blood (2023) 142 (Supplement 1): 5997.

https://doi.org/10.1182/blood-2023-185555

Published: 2023

Journal Articles

SIE/Sies/GITMO Criteria in Elderly Patients with Acute Myeloid Leukemia (AML): Useful Also in the New Drug Era? a Multicentric Real-Life Study By the Hematological Network Rete Ematologica Lombarda (REL)

Blood (2023) 142 (Supplement 1): 956.

https://doi.org/10.1182/blood-2023-180568

Published: 2023

Journal Articles

Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian Study

Blood (2023) 142 (Supplement 1): 731.

https://doi.org/10.1182/blood-2023-189025

Published: 2023

Journal Articles

Evolutionary Portrait of Adult Core-Binding Factor Leukemia Patients Treated with a Continuation Therapy with Midostaurin: Preliminary Results

Blood (2022) 140 (Supplement 1): 9054–9056.

https://doi.org/10.1182/blood-2022-160024

Published: 2022

Journal Articles

INO-CD22: A Multi-Center, Real-Life Study on Inotuzumab-Ozogamicin Safety and Effectiveness in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Blood (2021) 138 (Supplement 1): 4391.

https://doi.org/10.1182/blood-2021-149157

Published: 2021

Journal Articles

Prospective Evaluation of a Continuation Therapy with Midostaurin in Adult Patients with Core-Binding Factor Leukemia and Integrated Genetic Analysis: A Multi Center Phase II Study. Preliminary Results

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-137092

Published: 2020

Journal Articles

Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients

Diletta Fontana, PhD, Daniele Ramazzotti, PhD, Andrea Aroldi, MD, Antonio Niro, MS, Luca Massimino, PhD, Delphine Rea, MD, Fabio Stagno, MD, Bruno Martino, MD, Leonardo Campiotti, MD, Giovanni Caocci, MD, Elena Maria Elli, MD, Monica Fumagalli, MD, Fabio Ciceri, MD, Rocco Piazza, MD PhD, Carlo Gambacorti-Passerini, MD

Blood (2019) 134 (Supplement_1): 1714.

https://doi.org/10.1182/blood-2019-126467

Published: 2019

Journal Articles

Acute Leukemia and High-Risk Myelodysplastic Syndromes in HIV-Positive Patients: 25-Years' Experience of the Rete Ematologica Lombarda (REL)

Chiara Cattaneo, MD, Massimo Bernardi, MD, Valentina Mancini, MD, Chiara Pagani, MD, Monica Fumagalli, MD, Patrizia Zappasodi, MD, Erika Borlenghi, MD, Alessandro Re, MD, Fabio Ciceri, MD, Margherita Sciumé, Roberto Cairoli, MD, Giuseppe Rossi

Blood (2019) 134 (Supplement_1): 3603.

https://doi.org/10.1182/blood-2019-125288

Published: 2019

Journal Articles

Treatment of Elderly Patients with Acute Promyelocytic Leukemia: A Real Life Experience of the "Rete Ematologica Lombarda"

Valentina Mancini, MD, Erika Borlenghi, MD, Livia Leuzzi, MD, Claudia Basilico, MD, Massimo Bernardi, MD, Patrizia Zappasodi, MD, Monica Fumagalli, MD, Elisabetta Todisco, MD PhD, Chiara Cattaneo, MD, Federico Lussana, MD, Giambattista Bertani, MD, Erika Ravelli, MD, Nicola Fracchiolla, Mauro Turrini, Giuseppe Rossi, Silvia Cantoni, Roberto Cairoli, MD

Blood (2019) 134 (Supplement_1): 3862.

https://doi.org/10.1182/blood-2019-130089

Published: 2019

Journal Articles

Efficacy and Safety of Decitabine As First-Line Therapy for Elderly Patients with Acute Myeloid Leukemia.a Real Life Multicentric Experience of the Northern Italy

Blood (2017) 130 (Supplement 1): 1315.

https://doi.org/10.1182/blood.V130.Suppl_1.1315.1315

Published: 2017

Journal Articles

Final Results of Northern Italy Leukemia Group (NILG) Trial 10/07 Combining Pediatric-Type Therapy with Minimal Residual Disease Study and Risk-Oriented Hematopoietic Cell Transplantation in Adult Acute Lymphoblastic Leukemia (ALL)

Blood (2016) 128 (22): 176.

https://doi.org/10.1182/blood.V128.22.176.176

Published: 2016

Journal Articles

Real Life Analysis of the Rete Ematologica Lombarda on ELN Favorable Acute Myeloid Leukemia: The Molecular Remission Is a Necessary Goal for a Good Outcome in All Different Cytogenetic/Molecular Subgroups

Patrizia Zappasodi, MD, Laura Marbello, MD, Erika Borlenghi, MD, Monica Fumagalli, MD, Massimo Bernardi, MD, Nicola Stefano Fracchiolla, MD, Matteo Da Vià, MD, Marianna Rossi, MD, Emanuele Ravano, MD, Elisa Cerqui, MD, Virginia Valeria Ferretti, PhD, Mario Cazzola, Prof, Carlo Castagnola, MD, Giuseppe Rossi, MD

Blood (2015) 126 (23): 3740.

https://doi.org/10.1182/blood.V126.23.3740.3740

Published: 2015

Journal Articles

Phase II Randomized Trial Of Radiation-Free Central Nervous System (CNS) Prophylaxis Comparing Intrathecal Triple Therapy With Liposomal Cytarabine (DepoCyte ® ) In Adult Acute Lymphoblastic Leukemia (ALL)

Blood (2013) 122 (21): 3901.

https://doi.org/10.1182/blood.V122.21.3901.3901

Published: 2013

Journal Articles

Pediatric-Type Therapy Including Lineage-Targeted Methotrexate to Improve Early Minimal Residual Disease Response and Survival In Adult Acute Lymphoblastic Leukemia (ALL): Interim Analysis of Northern Italy Leukemia Group Study 10/07

Blood (2010) 116 (21): 2131.

https://doi.org/10.1182/blood.V116.21.2131.2131

Published: 2010

NARROW

Italian Real-World Experience of Gilteritinib Monotherapy in Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Preliminary Results

Rare Types of NPM1 Mutations Share a Similar Molecular Background to the Common NPM1 Variant and Have No Impact on Survival in Adults with Acute Myeloid Leukemia

Outpatient Administration of First Cycle Azacitidine-Venetoclax in Acute Myeloid Leukemia Patients Compared to Inpatient Care: Preliminary Results of a Single-Center Retro-Prospective Study

Final Analysis of the Italian Campus ALL Observational Study on 476 Older Patients with Philadelphia-Negative Acute Lymphoblastic Leukemia

CPX-351 Induces High Rate of Complete Remission in the New ICC/ELN 2022 Adverse-Risk Entity ‘AML with MDS-Related Gene Mutations’: Evidence from a Large Real-World Italian Study

Multiparametric Flow Cytometry-MRD Assay: Lesson from Phase II Trail REL AML 001

SIE/Sies/GITMO Criteria in Elderly Patients with Acute Myeloid Leukemia (AML): Useful Also in the New Drug Era? a Multicentric Real-Life Study By the Hematological Network Rete Ematologica Lombarda (REL)

Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian Study

Evolutionary Portrait of Adult Core-Binding Factor Leukemia Patients Treated with a Continuation Therapy with Midostaurin: Preliminary Results

INO-CD22: A Multi-Center, Real-Life Study on Inotuzumab-Ozogamicin Safety and Effectiveness in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Prospective Evaluation of a Continuation Therapy with Midostaurin in Adult Patients with Core-Binding Factor Leukemia and Integrated Genetic Analysis: A Multi Center Phase II Study. Preliminary Results

Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients

Acute Leukemia and High-Risk Myelodysplastic Syndromes in HIV-Positive Patients: 25-Years' Experience of the Rete Ematologica Lombarda (REL)

Treatment of Elderly Patients with Acute Promyelocytic Leukemia: A Real Life Experience of the "Rete Ematologica Lombarda"

Efficacy and Safety of Decitabine As First-Line Therapy for Elderly Patients with Acute Myeloid Leukemia.a Real Life Multicentric Experience of the Northern Italy

Final Results of Northern Italy Leukemia Group (NILG) Trial 10/07 Combining Pediatric-Type Therapy with Minimal Residual Disease Study and Risk-Oriented Hematopoietic Cell Transplantation in Adult Acute Lymphoblastic Leukemia (ALL)

Real Life Analysis of the Rete Ematologica Lombarda on ELN Favorable Acute Myeloid Leukemia: The Molecular Remission Is a Necessary Goal for a Good Outcome in All Different Cytogenetic/Molecular Subgroups

Phase II Randomized Trial Of Radiation-Free Central Nervous System (CNS) Prophylaxis Comparing Intrathecal Triple Therapy With Liposomal Cytarabine (DepoCyte ® ) In Adult Acute Lymphoblastic Leukemia (ALL)

Pediatric-Type Therapy Including Lineage-Targeted Methotrexate to Improve Early Minimal Residual Disease Response and Survival In Adult Acute Lymphoblastic Leukemia (ALL): Interim Analysis of Northern Italy Leukemia Group Study 10/07

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only